
|Videos|April 28, 2022
Tarsus pipeline advances program for Demodex blepharitis
Author(s)Kassi Filkins
Last year, the company announced the data from the Saturn-1 study for TP-03, the first potential product to treat Demodex blepharitis, and the product is now in the phase 3 trial (Saturn-2). Aziz Mottiwala, chief commercial officer for Tarsus, gives a company update on the pipeline for their program for Demodex blepharitis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Sharper vision starts here
2
Oculis to launch PIONEER trials for privosegtor in acute optic neuritis and NAION
3
iOpeners: Zubair Ansari, MD, shares his global health journey with Nicole Bajic, MD
4
Study finds retinal progenitor cell injections improve outcomes in rat model of diabetic retinopathy
5